Exiqon, a leading supplier of high-value gene expression analysis products, has launched its new Next Generation Sequencing services for microRNAs and other RNAs. Exiqon’s Next Generation Sequencing services provide a complete sample-to-answer solution including biological interpretation of customer’s results.
Results are delivered within four to six weeks of sample submission. All customers receive results and data analyses in the form of a highly advanced interactive report. The interactive report summarizes results in simple tables and diagrams and provides easy access to identify interesting microRNAs and genes through use of Exiqon’s proprietary miRSearch bioinformatics search tool which saves time and effort compared to traditional literature and database searches by rapidly presenting relevant information.
“This product offering is based on years of collaboration with our customers and numerous man-years of product development. Valuable customer input has defined the importance of combining high quality, fast turnaround time and thorough in depth reporting that can be readily understood by customers without prior training in Next Generation Sequencing” said senior vice president Sales & Marketing, Dr Henrik M Pfundheller.
The new offer for Next Generation Sequencing services complements Exiqon’s existing portfolio of services for qPCR and microarray profiling and allows Exiqon to leverage nine years of experience in servicing customers with high quality data through modern service laboratories.
Exiqon’s Next Generation Sequencing services integrate technical support in the planning phase with advanced sample preparation, library preparation, sequence generation based on state-of-the- art equipment and proprietary data analysis. These services address the need in basic research to reveal known as well as unknown microRNAs and other RNAs. Exiqon also offers a full range of LNATM-enhanced qPCR products for validation of targets identified by Next Generation Sequencing and LNATM products for any down-stream functional analysis.
Exiqon's products are based on the proprietary LNATM technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine.